AIDS 2022 preview – Gilead shoots for an HIV cure

AIDS 2022 preview – Gilead shoots for an HIV cure

Source: 
EP Vantage
snippet: 

Gilead has already shot itself in the foot once – from a business perspective at least – by curing hepatitis C. Now the company hopes to do it again with HIV. At the Aids 2022 meeting this weekend the group will present early data with two of its curative efforts, the toll-like receptor 7 agonist vesatolimod and a Flt3 agonist, during a late-breaking session.